Epidemiological Features of Clostridioides difficile Infection During the COVID-19 Pandemic
DOI:
https://doi.org/10.52556/2587-3873.2024.4(101).08Keywords:
Clostridioides diffi cile infections, pseudomembranouscolitis, nosocomial diseases, prevention, microbiome, vancomycinAbstract
During the COVID-19 pandemic, with a colossal use of antibiotics and immunity problems resulting from SARS-CoV-2, vigilance through C. diffi cile infections has increased and requires urgent action to address this problem. A retrospective study was carried out in one of the medical institutions in Chisinau municipality, in which the medical records of all adult patients (aged ≥ 18 years) with positive samples for CDI were analyzed between January 2020 and December 2023. As a result of the study, out of 106 patients diagnosed with CDI, 56% tested positive within 7 days of admission. We found that 71% (69/106) of the patients admitted with ICD were aged > 60 years, with female predominance. Analysis of antibiotic use among CDI positive cases showed that the majority were on vancomycin (89%) metronidazole (33%), amoxicillin (22%) and last resort antibiotic - colistin (19%). Infection caused by Clostridioides diffi cile more commonly aff ects people aft er 60 years of age. Risk factors in the development of CDI, were found: hospitalization in the last 30 days, older age, female sex, COVID-19 infection, chemotherapies, hypertension etc. The incidence of the disease is observed more for the year 2021, being associated with empirical antibiotic treatments administered intensively during COVID-19.
References
1. CLOVID STUDY GROUP. The Burden of Clostridioides Difficile Infection during the COVID-19 Pandemic: A Retrospective Case-Control Study in Italian Hospitals. In: Journal of Clinical Medicine. 2020, nr. 9(12), p. 3855. https://doi.org/10.3390/jcm9123855
2. CRNOKRAK, B., POPADIC, V., RADOJEVIC, A. et al. Incidence and Risk Factors for Clostridioides difficile Infections in Non-COVID and COVID-19 Patients: Experience from a Tertiary Care Hospital. In: Microorganisms. 2023, nr. 11(2), p. 435. https://doi.org/10.3390/microorganisms11020435
3. DA SILVA, S.G., DE OLIVEIRA, R.C., CAETANO, C.R. Epidemiological and clinical characteristics of Clostridioides difficile infection during the COVID-19 pandemic: A case-control study. In: Clinical Microbiology and Infection. 2022, nr. 28(4), pp. 587.e1-587.e5.
4. D'ALOISIO, L., CONSONNI, A., NOVIELLO, D. et al. Clostridioides difficile infection in COVID-19 patients: An underestimated problem? In: Journal of Infection and Public Health. 2022, nr. 15(1), pp. 56-60.
5. DOLL, M., MARRA, A.R., APISARNTHANARAK, A. et al. Prevention of Clostridioides difficile in hospitals: A position paper of the International Society for Infectious Diseases. In: International Journal of Infectious Diseases. 2021, nr. 102, pp. 188-195. https://doi.org/10.1016/j.ijid.2020.10.039
6. MARKANTONIS, J.E., FALLON, J.T., MADAN, R. et al. Clostridioides difficile Infection: Diagnosis and Treatment Challenges. In: Pathogens. 2024, nr. 13(2), p. 118. https://doi.org/10.3390/pathogens13020118
7. MARRA, R. et al. Incidence and Outcomes Associated With Clostridium difficile Infections.In: JAMA Netw Open. 2020, nr. 3(1), p. e1917597. https://doi.org/10.1001/jamanetworkopen.2019.17597
8. PETROSILLO, N., RAVASIO, R. Il Costo Ospedaliero di Trattamento di un Episodio di Infezione da Clostridium Difficile in Italia. In: Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. 2017, nr. 4(1), p. grhta.5000257. https://doi.org/10.5301/grhta.5000257
9. RODRÍGUEZ-BAÑO, J., CANTÓN, R., MARTÍNEZ-GARCÍA, J.A. et al. Impact of the coronavirus disease 2019 (COVID-19) pandemic on nosocomial Clostridioides difficile infection. In: Infection Control & Hospital Epidemiology. 2021, nr. 42(8), pp. 1003-1006.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
